- World's First Stem Cell Therapy, Designated as Orphan Drug by US FDA!
- Monopoly on the 20 Trillion KRW Lou Gehrig's Disease Treatment Market Imminent! Another 1,700% ShillaJen is Coming!
◈ 2,000% Surge Material! Stem Cell Bio! The Second ShillaJen Emerges! ▶3-Day Free Application◀
This stock, which successfully developed the world's first stem cell therapy for Lou Gehrig's disease, like Green Cross Cell, has been designated as an orphan drug by the US FDA, granting it exclusive rights for 7 years.
◈ The Second ShillaJen! Finally Starting to Rise! ▶3-Day Free Application◀
The global market size for Lou Gehrig's disease is estimated at approximately 20 trillion KRW. Since July 2017, the number of overseas Lou Gehrig's patients entering Korea for treatment has been increasing, and policy support such as drug price negotiations for domestic health insurance listing is also expected to proceed.
"I applied for the 3-day trial with the mindset that I couldn't lose anything, but with AI plus care from elite foreign experts, it was definitely different. I earned 5 million KRW in 3 days. Now, I plan to focus my investment in this area." (Full-time housewife Kim Mi-jung, 49 years old, VIP member candidate)
◈ The Second ShillaJen Goes Twice as High This Time! 3000% Follow-up Stock! ▶ Click Here ◀
While the domestic pharmaceutical bio sector, which had been struggling, is expected to show signs of recovery in the second half of this year, some stocks that remained silent despite favorable factors are re-emerging, presenting a golden opportunity for a life turnaround.
※ Limited to the first 10 applicants! Recruiting the hero of the bottom of the 9th inning, 2 outs, walk-off grand slam ※
※ Limited to the first 10 applicants! Please understand early closure due to overwhelming applications. ※
[Today's Stocks of Interest]
EyesVision Namseon Aluminum Mercury Peace Holdings Qurocom
※ This content is unrelated to the editorial direction of Asia Economy, and all responsibility lies with the information provider.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
